BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18042714)

  • 1. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
    Adimoolam S; Sirisawad M; Chen J; Thiemann P; Ford JM; Buggy JJ
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19482-7. PubMed ID: 18042714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells.
    Du LQ; Du XQ; Bai JQ; Wang Y; Yang QS; Wang XC; Zhao P; Wang H; Liu Q; Fan FY
    J Cancer Res Clin Oncol; 2012 May; 138(5):811-8. PubMed ID: 22274865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing CRISPR/Cas9-mediated homology-directed DNA repair by histone deacetylase inhibitors.
    Li G; Zhang X; Wang H; Liu D; Li Z; Wu Z; Yang H
    Int J Biochem Cell Biol; 2020 Aug; 125():105790. PubMed ID: 32534122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
    Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
    Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.
    Ladd B; Ackroyd JJ; Hicks JK; Canman CE; Flanagan SA; Shewach DS
    DNA Repair (Amst); 2013 Dec; 12(12):1114-21. PubMed ID: 24231389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization by the histone deacetylase inhibitor PCI-24781.
    Banuelos CA; Banáth JP; MacPhail SH; Zhao J; Reitsema T; Olive PL
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6816-26. PubMed ID: 18006784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
    Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
    Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
    Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
    Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
    Tsai CL; Liu WL; Hsu FM; Yang PS; Yen RF; Tzen KY; Cheng AL; Chen PJ; Cheng JC
    Hepatology; 2018 Feb; 67(2):586-599. PubMed ID: 28646552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
    Park JM; Huang S; Tougeron D; Sinicrope FA
    PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.
    Konsoula Z; Cao H; Velena A; Jung M
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1541-8. PubMed ID: 21277099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
    Hegan DC; Lu Y; Stachelek GC; Crosby ME; Bindra RS; Glazer PM
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2201-6. PubMed ID: 20133863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
    Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
    Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.